Company research
Lexaria Bioscience Corp.
CIK 1348362Updated Sep 24, 2026
SecurityLEXX · NASDAQ · equity
Historical securities (1)
LEXXW · NASDAQ · warrant · closed Jan 14, 2026Name history
Lexaria Corp. · through May 11, 2016LEXARIA CORP. · through May 11, 2016
LEXX price & chart
Loading TradingView…
NASDAQ:LEXX on TradingView ↗About the company
Lexaria is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
In the news
No coverage from other publishers is available.
Recent filings
D filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Other Events
Items 8.01
Other Events
Items 8.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 4,175,121Source | 8,867,789Source | 3,083,986Source | 7,833,927Source |
| Property, Plant and Equipment, NetUSD | 228,129Source | 254,709Source | 254,143Source | 315,505Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 5,813,218Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 368,358Source | 154,477Source | 175,245Source | 201,784Source |
| Inventory, NetUSD | — | — | 0Source | 38,418Source |
| Assets, CurrentUSD | 3,468,345Source | 7,897,986Source | 2,199,772Source | 6,977,516Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,132,504Source | 1,187,817Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 134,843Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,572,366Source | 1,208,738Source | 403,908Source | 201,437Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 19,559Source | 15,810Source | 8,091Source | 5,951Source |
| Additional Paid in CapitalUSD | 66,501,086Source | 59,599,178Source | 48,799,454Source | 47,041,481Source |
| Retained Earnings (Accumulated Deficit)USD | -63,460,613Source | -51,558,772Source | -45,763,427Source | -39,098,528Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -70,335Source | -19,816Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 2,989,697Source | 8,036,400Source | 3,044,118Source | 7,948,904Source |
| Liabilities and EquityUSD | 4,175,121Source | 8,867,789Source | 3,083,986Source | 7,833,927Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,493,463Source | 1,099,419Source | 267,735Source | 194,036Source |
| Operating Lease, Liability, CurrentUSD | 30,417Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 78,903Source | — | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | -377,349Source | -364,040Source | -316,414Source |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 0Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -11,911,434Source | -5,808,654Source | -6,712,525Source | 7,383,653Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 51,225Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 859,494Source | 492,236Source | 170,382Source | 752,591Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 213,881Source | 35,551Source | 26,539Source | 137,491Source |
| Increase (Decrease) in InventoriesUSD | — | 0Source | 43,069Source | 1,979Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -10,450,387Source | -4,959,003Source | -5,881,237Source | -4,879,339Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -243,019Source | -188,605Source | -169,610Source | -180,640Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 24,646Source | 43,014Source | 33,748Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,046,163Source | — | 1,589,731Source | -44,600Source |
| Repayments of Long-term DebtUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -4,697,762Source | 5,147,783Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,802,123Source | 6,499,885Source | 1,352,102Source | 5,813,218Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -50,519Source | — | — | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | 9,047Source | — | — | — |
| AmortizationUSD | -51,225Source | 0Source | 4,651Source | 3,655Source |
| Share-based Payment Arrangement, ExpenseUSD | 859,494Source | — | 170,382Source | 752,591Source |
| Amortization of Intangible AssetsUSD | 36,600Source | — | — | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | 0Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | 0Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | 1,522,704Source |
| Gain (Loss) on InvestmentsUSD | 33,540Source | — | — | — |
| Gain (Loss) on Sales of Loans, NetUSD | — | — | — | -7,926Source |
| General and Administrative ExpenseUSD | 4,345,183Source | 3,852,021Source | 3,062,009Source | 5,724,534Source |
| Goodwill, Impairment LossUSD | — | 57,836Source | 106,761Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | 247,364Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -7,383,653Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Inventory Write-downUSD | 213,824Source | — | 38,418Source | 0Source |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | -69,835Source | -221,693Source | — |
| Marketable Securities, Unrealized Gain (Loss)USD | -33,714Source | -69,835Source | -221,693Source | -764,614Source |
| Net Income (Loss) Attributable to ParentUSD | -11,901,841Source | -5,795,345Source | -6,664,899Source | -7,269,324Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -9,593Source | -13,309Source | -47,626Source | -114,329Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -7,269,324Source |
| Nonoperating Income (Expense)USD | -30,697Source | — | — | — |
| Operating Costs and ExpensesUSD | — | — | 167,446Source | 52,444Source |
| Operating ExpensesUSD | 12,583,940Source | 6,212,586Source | 6,728,730Source | 7,567,209Source |
| Operating Lease, Impairment LossUSD | — | 57,836Source | 106,761Source | — |
| Other Nonoperating Income (Expense)USD | — | -55,524Source | -178,503Source | — |
| Proceeds from Issuance of Common StockUSD | 6,046,163Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 0Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 464,278Source | 226,208Source | 255,397Source |
| Cost of RevenueUSD | 2,720Source | 4,822Source | 31,500Source | 71,841Source |
| Operating Income (Loss)USD | -11,880,737Source | -5,753,130Source | -6,534,022Source | -7,383,653Source |
| Other Nonoperating Income (Expense)USD | — | -55,524Source | -178,503Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -11,911,434Source | -5,808,654Source | -6,712,525Source | -7,383,653Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -9,593Source | -13,309Source | -47,626Source | -114,329Source |
| Net Income (Loss) Attributable to ParentUSD | -11,901,841Source | -5,795,345Source | -6,664,899Source | -7,269,324Source |
| Earnings Per Share, DilutedUSD per share | -0.66Source | -0.47Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 17,998,715Source | 12,383,974Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 36,600Source | — | — | — |
| Cost, Depreciation and AmortizationUSD | 0Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 87,825Source | 76,153Source | 145,397Source | 102,718Source |
| Gain (Loss) on InvestmentsUSD | 33,540Source | — | — | — |
| General and Administrative ExpenseUSD | 4,345,183Source | 3,852,021Source | 3,062,009Source | 5,724,534Source |
| Goodwill, Impairment LossUSD | — | 57,836Source | 106,761Source | — |
| Gross ProfitUSD | 703,203Source | 459,456Source | 194,708Source | 183,556Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -7,383,653Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Interest Income (Expense), NetUSD | — | 14,311Source | — | — |
| Interest Income, OtherUSD | 3,017Source | 14,117Source | 43,190Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -7,269,324Source |
| Nonoperating Income (Expense)USD | -30,697Source | — | — | — |
| Operating Costs and ExpensesUSD | — | — | 167,446Source | 52,444Source |
| Operating ExpensesUSD | 12,583,940Source | 6,212,586Source | 6,728,730Source | 7,567,209Source |
| Research and Development ExpenseUSD | 8,238,757Source | 2,360,565Source | 3,666,721Source | 1,842,675Source |
Offerings
Registration 333-290862
Filing attachments
lxrp_ex41.htm · 8-K · 2026-09-09
EX-4.1 2 lxrp_ex41.htm FORM OF COMMON WARRANT lxrp_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITI…
Read attachment ↗lxrp_ex42.htm · 8-K · 2026-09-09
EX-4.2 3 lxrp_ex42.htm FORM OF PLACEMENT AGENT WARRANT lxrp_ex42.htm EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE…
Read attachment ↗lxrp_ex991.htm · 8-K · 2026-09-09
EX-99.1 5 lxrp_ex991.htm PRESS RELEASE lxrp_ex991.htm EXHIBIT 99.1 Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds Tuesday, 08 September 2026 08:00 AM Topic: Financing KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstandin…
Read attachment ↗lxrp_ex991.htm · 8-K · 2026-07-30
EX-99.1 3 lxrp_ex991.htm PRESS RELEASE lxrp_ex991.htm EXHIBIT 99.1 Lexaria Announces Effective Date for Reverse Stock Split Kelowna, British Columbia - July 30, 2026 - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it intends to effect a reverse stock split of its common stock effective as of 12:01 am EST on August 3, 2026 (the “Reverse Split”). The primary goal of the Reverse Split is to increase the pe…
Read attachment ↗lxrp_ex41.htm · 8-K · 2025-12-16
EX-4.1 2 lxrp_ex41.htm COMMON STOCK PURCHASE WARRANT lxrp_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE S…
Read attachment ↗lxrp_ex42.htm · 8-K · 2025-12-16
EX-4.2 3 lxrp_ex42.htm PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT lxrp_ex42.htm EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE…
Read attachment ↗